Tuesday, November 17, 2026

How Much Further Can the New Drug 'Ripiktu' Grow in Market Value? Expansion Beyond Cholangiocarcinoma into Solid Tumors

Input
2026-10-01 10:17:31
Updated
2026-10-01 10:17:31
Provided by HLB

[Financial News] With Elevar Therapeutics, HLB's U.S. subsidiary, securing U.S. Food and Drug Administration (FDA) approval for the FGFR2-targeted anticancer drug 'Ripiktu' (active ingredient: lirafugratinib), attention is turning to the drug's medium- to long-term value and its potential expansion into additional indications.
Selective and irreversible FGFR2 inhibition sets it apart from existing treatments
According to HLB on the 1st, Ripiktu's first commercial indication is cholangiocarcinoma with FGFR2 fusions or rearrangements. However, the potential that the company identified early in development is not limited to treating cholangiocarcinoma. Since FGFR2 alterations are also found in various solid tumors, expanding treatment to other cancer types with this biomarker could broaden the drug's applications and increase its market value. When licensing the drug, Elevar also identified its high selectivity for FGFR2, existing clinical data, and potential for expansion into various solid tumors with FGFR2 alterations as key elements of Ripiktu's value.
Although cholangiocarcinoma does not have a large patient population, it is a rare cancer with limited treatment options. FGFR2 fusions and rearrangements are found in approximately 10% of all cholangiocarcinoma patients and about 15% of patients with intrahepatic cholangiocarcinoma. An HLB official explained, "Ripiktu's core competitive advantage is its high selectivity for FGFR2. While previously approved FGFR inhibitors use a 'pan-FGFR' approach that broadly inhibits FGFR1 through FGFR4, Ripiktu was designed to selectively and irreversibly inhibit FGFR2."
In preclinical studies, Ripiktu showed more than 250-fold selectivity over FGFR1 and more than 5,000-fold selectivity over FGFR4. In the global Phase 1/2 REFOCUS trial, the drug recorded an objective response rate (ORR) of 45.7%, a median duration of response (mDOR) of 11.8 months, a median progression-free survival (mPFS) of 11.3 months, and a median overall survival (mOS) of 22.8 months.
The ORRs reported in pivotal clinical trials of the previously approved drugs pemigatinib and Futibatinib were 37% and 41.7%, respectively, while their mDORs were 9.1 months and 9.7 months, respectively. Ripiktu showed numerically higher results on these measures.
Expanding from cholangiocarcinoma into FGFR2-based tumor-agnostic treatment
Expanding its indications is the key task for increasing Ripiktu's medium- to long-term value. FGFR2 alterations may contribute to the development and growth of various solid tumors, including pancreatic, gastric, lung, and ovarian cancers, in addition to cholangiocarcinoma.
Elevar is currently conducting the global Phase 2 ReFocus202 trial at clinical institutions in South Korea, the United States, and Europe among patients with solid tumors other than cholangiocarcinoma. The researchers are evaluating Ripiktu's antitumor activity, focusing on the objective response rate.
Tumor-agnostic treatment selects patients based on specific genetic mutations or biomarkers rather than the organ in which the cancer originated. If Ripiktu expands its approval to become a tumor-agnostic treatment for cancers with FGFR2 alterations, it could potentially be used in a broad range of solid tumor patients beyond those with cholangiocarcinoma.
Related studies have also identified FGFR2 alterations across multiple cancer types. In a 2016 analysis of 4,853 solid tumor samples by a research team at the University of California, San Diego (UCSD), FGFR2 alterations were found in approximately 1.5% of all samples. A 2022 study by a Samsung Medical Center research team analyzing 1,373 patients with metastatic gastrointestinal and genitourinary cancers found FGFR2 amplifications and fusions in 1.5% and 1.1% of patients, respectively.
An industry source noted, "Because the two studies differed in their subjects and the types of genetic alterations analyzed, it is difficult to interpret their results using the same criteria. Nevertheless, they suggest that patients with FGFR2-related genetic alterations exist across multiple cancer types and that a considerable proportion of newly diagnosed cancer patients each year could potentially be included among the treatment candidates."
Elevar is maintaining a cautious position regarding the expansion of the treatment population. Once it reaches the stage of securing a tumor-agnostic indication, the company is reportedly expected to prioritize patients in the United States, the United Kingdom, and Europe as treatment candidates. It plans to expand the patient population thereafter by securing additional indications and broadening its global presence.
An HLB official said, "After receiving FDA approval for cholangiocarcinoma, Ripiktu also demonstrated antitumor activity in patients with non-cholangiocarcinoma cancers in the existing REFOCUS trial, showing its potential for expansion based on FGFR2. If meaningful data are additionally secured in the tumor-agnostic trial, its treatment scope and value as a new drug could expand significantly."

[email protected] Choi Du-seon Reporter